Current Report Filing (8-k)
January 14 2022 - 5:14PM
Edgar (US Regulatory)
0001535955
false
0001535955
2022-01-14
2022-01-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported):
January
14, 2022
LIPOCINE
INC.
(Exact
name of registrant as specified in its charter)
Commission
File No. 001-36357
Delaware
|
|
99-0370688
|
(State
or other jurisdiction
of incorporation)
|
|
(IRS
Employer
Identification Number)
|
675
Arapeen Drive, Suite 202
Salt
Lake City, Utah 84108
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (801) 994-7383
Former
name or former address, if changed since last report: Not Applicable
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
I
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
|
LPCN
|
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§ 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of
Listing.
On January
14, 2022, Lipocine Inc. (“Lipocine”) received written notice from the staff (the “Staff”) of the Listing
Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating the
Company is no longer in compliance with Nasdaq Listing Rules set forth in Listing Rule 5605, which requires a majority independent board,
audit committee and compensation committee. Pursuant to Nasdaq Listing Rules 5605(b)(1)(A), 5605(c)(4) and 5605(d)(4), the Company is
entitled to a cure period to regain compliance with Nasdaq Listing requirements, which cure period will expire at the earlier of the
Company’s 2022 annual meeting of stockholders (the “2022 Annual Meeting”) or June 6, 2022. The Company intends to appoint
an additional independent director to the board of directors, audit committee and compensation committee prior to the end of the cure
period.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
LIPOCINE
INC.
|
|
|
|
|
|
Date:
|
January
14, 2022
|
|
By:
|
/s/
Mahesh V. Patel
|
|
|
|
|
Mahesh
V. Patel
|
|
|
|
|
President
and Chief Executive Officer
|
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Sep 2023 to Sep 2024